In the following video, Motley Fool health-care analyst David Williamson highlights one critical asset for pharmaceutical company Celgene (NASDAQ: CELG ) -- its management. He gives investors three factors that he sees as essential for the leader of any pharmaceutical company, and tells us how well Celgene's Chairman and CEO Bob Hugin stacks up to those criteria.
Can Celgene continue to soar?
Every in-the-know biotech investor has an eye on Celgene. Shares have skyrocketed this year as the company outlined a plan to almost triple its profits in only a few years. But should you buy the story Celgene is selling? Make sure you understand the key opportunities and risks facing this company by picking up The Motley Fool's brand new premium report on Celgene. To claim your copy today simply click here now.